301331 恩威医药
已收盘 05-19 15:00:00
资讯
新帖
简况
恩威医药(301331)披露2025年年度股东会决议公告,5月19日股价上涨0.68%
证券之星 · 05-19 18:23
恩威医药(301331)披露2025年年度股东会决议公告,5月19日股价上涨0.68%
恩威医药(301331)披露首次公开发行股票持续督导保荐总结报告书,5月15日股价下跌0.68%
证券之星 · 05-15
恩威医药(301331)披露首次公开发行股票持续督导保荐总结报告书,5月15日股价下跌0.68%
恩威医药:公司一贯重视市值管理工作
证券之星 · 05-14
恩威医药:公司一贯重视市值管理工作
恩威医药:2025-2027三年发展及增长计划,总目标是“三年番一翻”
证券之星 · 05-13
恩威医药:2025-2027三年发展及增长计划,总目标是“三年番一翻”
股市必读:恩威医药(301331)5月8日披露最新机构调研信息
证券之星 · 05-11
股市必读:恩威医药(301331)5月8日披露最新机构调研信息
每周股票复盘:恩威医药(301331)一季度净利降23.31%
证券之星 · 05-03
每周股票复盘:恩威医药(301331)一季度净利降23.31%
恩威医药:商誉相关资产组可收回金额大于其账面价值
证券之星 · 04-30
恩威医药:商誉相关资产组可收回金额大于其账面价值
恩威医药(301331)披露2026年一季度报告,4月27日股价下跌2.7%
证券之星 · 04-27
恩威医药(301331)披露2026年一季度报告,4月27日股价下跌2.7%
股市必读:恩威医药年报 - 第四季度单季净利润同比下降0.75%
中金财经 · 04-27
股市必读:恩威医药年报 - 第四季度单季净利润同比下降0.75%
恩威医药(301331)3月31日股东户数0.77万户,较上期增加14.45%
证券之星 · 04-26
恩威医药(301331)3月31日股东户数0.77万户,较上期增加14.45%
图解恩威医药年报:第四季度单季净利润同比下降0.75%
证券之星 · 04-26
图解恩威医药年报:第四季度单季净利润同比下降0.75%
恩威医药(301331)2名股东合计质押540万股,占总股本5.25%
证券之星 · 04-16
恩威医药(301331)2名股东合计质押540万股,占总股本5.25%
股市必读:恩威医药(301331)3月4日董秘有最新回复
证券之星 · 03-05
股市必读:恩威医药(301331)3月4日董秘有最新回复
恩威医药(301331)披露全资子公司取得换发《药品生产许可证》公告,2月24日股价上涨1.94%
证券之星 · 02-24
恩威医药(301331)披露全资子公司取得换发《药品生产许可证》公告,2月24日股价上涨1.94%
恩威医药(301331)披露控股股东部分股份解除质押公告,2月5日股价上涨0.1%
证券之星 · 02-05
恩威医药(301331)披露控股股东部分股份解除质押公告,2月5日股价上涨0.1%
恩威医药(301331)披露控股股东询价转让结果公告,2月2日股价上涨0.11%
证券之星 · 02-02
恩威医药(301331)披露控股股东询价转让结果公告,2月2日股价上涨0.11%
股市必读:恩威医药(301331)1月27日董秘有最新回复
证券之星 · 01-28
股市必读:恩威医药(301331)1月27日董秘有最新回复
恩威医药最新公告:控股股东拟询价转让400万股股份
证券之星 · 01-26
恩威医药最新公告:控股股东拟询价转让400万股股份
恩威医药最新公告:2025年净利润同比预增50.68%至77.35%
证券之星 · 01-20
恩威医药最新公告:2025年净利润同比预增50.68%至77.35%
恩威医药(301331)披露2025年中期分红派息实施公告,12月31日股价上涨0.23%
证券之星 · 2025-12-31
恩威医药(301331)披露2025年中期分红派息实施公告,12月31日股价上涨0.23%
加载更多
公司概况
公司名称:
恩威医药股份有限公司
所属行业:
医药制造业
上市日期:
2022-09-21
主营业务:
恩威医药股份有限公司的主营业务是中成药、化学药及健康私护用品的研发、生产及销售。公司的主要产品是洁尔阴洗液、洁尔阴软膏、洁尔阴泡腾片、恩威草本抑菌洗液、山麦健脾口服液、化积口服液、健儿药丸、小儿氨酚黄那敏颗粒、小儿咳喘灵颗粒、加味藿香正气合剂、复方氨酚烷胺片、复方银翘氨敏胶囊、抗病毒口服液、六味地黄胶囊、人参养荣膏、益肺健脾颗粒、玉屏风口服液。公司荣获2025年法国好设计奖、2025年美国好设计奖,产品还荣获“2025鸿鼎榜单10万+药房门店明星产品”荣誉称号。
发行价格:
29.80
{"stockData":{"symbol":"301331","market":"SZ","secType":"STK","nameCN":"恩威医药","latestPrice":26.59,"timestamp":1779174204000,"preClose":26.41,"halted":0,"volume":919100,"delay":0,"changeRate":0.0068,"floatShares":103000000,"shares":103000000,"eps":0.468,"marketStatus":"已收盘","change":0.18,"latestTime":"05-19 15:00:00","open":26.52,"high":26.83,"low":26.2,"amount":24414500,"amplitude":0.0239,"askPrice":26.59,"askSize":18,"bidPrice":26.57,"bidSize":76,"shortable":0,"etf":0,"ttmEps":0.468,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779240600000},"marketStatusCode":5,"adr":0,"adjPreClose":26.41,"symbolType":"stock","openAndCloseTimeList":[[1779154200000,1779161400000],[1779166800000,1779174000000]],"highLimit":29.05,"lowLimit":23.77,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":102891887,"isCdr":false,"pbRate":2.5,"roa":"--","peRate":56.816239,"roe":"1.16%","epsLYR":0.5048,"committee":-0.433155,"marketValue":2736000000,"turnoverRate":0.009,"status":0,"floatMarketCap":2729000000},"requestUrl":"/m/hq/s/301331","defaultTab":"news","newsList":[{"id":"2636701837","title":"恩威医药(301331)披露2025年年度股东会决议公告,5月19日股价上涨0.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636701837","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636701837?lang=zh_cn&edition=full","pubTime":"2026-05-19 18:23","pubTimestamp":1779186195,"startTime":"0","endTime":"0","summary":"截至2026年5月19日收盘,恩威医药报收于26.59元,较前一交易日上涨0.68%,最新总市值为27.36亿元。恩威医药于近日披露《2025年年度股东会决议公告》。公告显示,公司于2026年5月18日召开2025年年度股东会,会议由董事会召集,董事长薛永江主持,采用现场与网络投票结合方式召开。出席会议股东及代理人共39人,代表股份64,536,259股,占公司有表决权股份总数的63.3481%。所有议案均获表决通过,无否决议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900035358.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635083971","title":"恩威医药(301331)披露首次公开发行股票持续督导保荐总结报告书,5月15日股价下跌0.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635083971","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635083971?lang=zh_cn&edition=full","pubTime":"2026-05-15 18:14","pubTimestamp":1778840060,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘,恩威医药报收于26.45元,较前一交易日下跌0.68%,最新总市值为27.21亿元。公告显示,中信证券作为保荐机构,对恩威医药首次公开发行股票并在创业板上市后的持续督导工作进行总结。恩威医药于2022年9月21日在深交所创业板上市,股票代码301331.SZ,首次公开发行人民币普通股1754万股,募集资金净额4.43亿元,已按规定存放与使用,未发现违规情形。保荐机构将继续对募集资金使用履行督导义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500035271.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635710646","title":"恩威医药:公司一贯重视市值管理工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2635710646","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635710646?lang=zh_cn&edition=full","pubTime":"2026-05-14 20:51","pubTimestamp":1778763102,"startTime":"0","endTime":"0","summary":"感谢您对公司的关注,公司未来是否进行回购股份操作需要视具体情况而定。公司一贯重视市值管理工作,以抓好经营管理、不断提升企业内在价值为根本,同时通过积极分红回报投资者、回购公司股份、股东增持等多种途径提升投资者的投资体验,吸引包括机构投资者在内的更多投资者关注、投资本公司。未来公司将进一步加强与投资者沟通,实现公司价值的传递,保持与资本市场的良好互动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400040826.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635223204","title":"恩威医药:2025-2027三年发展及增长计划,总目标是“三年番一翻”","url":"https://stock-news.laohu8.com/highlight/detail?id=2635223204","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635223204?lang=zh_cn&edition=full","pubTime":"2026-05-13 16:48","pubTimestamp":1778662092,"startTime":"0","endTime":"0","summary":"证券之星消息,恩威医药05月13日在投资者关系平台上答复投资者关心的问题。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300030063.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634491426","title":"股市必读:恩威医药(301331)5月8日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2634491426","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634491426?lang=zh_cn&edition=full","pubTime":"2026-05-11 03:16","pubTimestamp":1778440570,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘,恩威医药报收于27.25元,上涨0.78%,换手率1.13%,成交量1.16万手,成交额3137.95万元。来自机构调研要点:恩威医药维持“三年番一翻”发展目标,2026年为关键执行年份,信心药业产品线成为核心增量来源。二级市场股价受宏观经济、行业景气度、市场偏好及投资者认知等多重因素影响。公司2025-2027年总体目标为“三年番一翻”。尽管2025年因信心药业产品复产手续延迟导致部分预期未达,但整体发展趋势向好。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100001521.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632608679","title":"每周股票复盘:恩威医药(301331)一季度净利降23.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632608679","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632608679?lang=zh_cn&edition=full","pubTime":"2026-05-03 08:18","pubTimestamp":1777767495,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘,恩威医药报收于27.11元,较上周的26.68元上涨1.61%。业绩披露要点恩威医药2026年第一季度报告显示,当期营业收入为175,328,944.36元,同比下降10.77%;归属于上市公司股东的净利润为12,504,732.32元,同比下降23.31%;扣除非经常性损益后的净利润为10,695,869.85元,同比下降26.86%。加权平均净资产收益率为1.16%,较上年同期下降0.37个百分点。经营活动产生的现金流量净额为10,959.29万元,同比增长38.87%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050300002049.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631508898","title":"恩威医药:商誉相关资产组可收回金额大于其账面价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2631508898","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631508898?lang=zh_cn&edition=full","pubTime":"2026-04-30 11:36","pubTimestamp":1777520172,"startTime":"0","endTime":"0","summary":"证券之星消息,恩威医药(301331)04月29日在投资者关系平台上答复投资者关心的问题。投资者提问:2025年,公司商誉达到总资产的6.48%,但商誉减值准备为0%,请问公司是否利用商誉减值调节利润?恩威医药回复:您好!2025年末公司恩威江西商誉的账面价值为人民币1.0055亿元,经聘请的专业评估机构评估并出具资产评估报告,截至2025年末,商誉相关资产组可收回金额大于其账面价值,无需计提减值。感谢您对公司的关注!谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000039233.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630360622","title":"恩威医药(301331)披露2026年一季度报告,4月27日股价下跌2.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630360622","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630360622?lang=zh_cn&edition=full","pubTime":"2026-04-27 18:36","pubTimestamp":1777286173,"startTime":"0","endTime":"0","summary":"截至2026年4月27日收盘,恩威医药报收于25.96元,较前一交易日下跌2.7%,最新总市值为26.71亿元。该股当日开盘25.85元,最高26.08元,最低24.86元,成交额达7288.1万元,换手率为2.8%。恩威医药于2026年4月27日披露《2026年第一季度报告》。报告显示,公司本报告期营业收入为175,328,944.36元,较上年同期下降10.77%;归属于上市公司股东的净利润为12,504,732.32元,同比下降23.31%;扣除非经常性损益后的净利润为10,695,869.85元,同比下降26.86%。加权平均净资产收益率为1.16%,较上年同期下降0.37个百分点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700034988.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630330863","title":"股市必读:恩威医药年报 - 第四季度单季净利润同比下降0.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630330863","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630330863?lang=zh_cn&edition=full","pubTime":"2026-04-27 08:55","pubTimestamp":1777251310,"startTime":"0","endTime":"0","summary":"来自股本股东变化:截至2026年3月31日,公司股东户数环比增长14.45%,户均持股数量降至1.33万股。来自业绩披露要点:2025年公司归母净利润同比增长38.53%,达5194.49万元,盈利能力显著提升。来自公司公告汇总:2026年第一季度净利润同比下降23.31%,经营现金流由正转负,同比减少114.15%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260427/32178262.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["301331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630367384","title":"恩威医药(301331)3月31日股东户数0.77万户,较上期增加14.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630367384","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630367384?lang=zh_cn&edition=full","pubTime":"2026-04-26 17:15","pubTimestamp":1777194937,"startTime":"0","endTime":"0","summary":"证券之星消息,近日恩威医药披露,截至2026年3月31日公司股东户数为7731.0户,较12月31日增加976.0户,增幅为14.45%。在中药行业个股中,恩威医药股东户数低于行业平均水平,截至3月31日,中药行业平均股东户数为5.3万户。从股价来看,2025年12月31日至2026年3月31日,恩威医药区间跌幅为0.8%,在此期间股东户数增加976.0户,增幅为14.45%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600011428.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630817643","title":"图解恩威医药年报:第四季度单季净利润同比下降0.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630817643","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630817643?lang=zh_cn&edition=full","pubTime":"2026-04-26 17:05","pubTimestamp":1777194306,"startTime":"0","endTime":"0","summary":"证券之星消息,恩威医药2025年年报显示,当年度公司主营收入9.01亿元,同比上升10.91%;归母净利润5194.49万元,同比上升38.53%;扣非净利润4652.29万元,同比上升33.96%;其中2025年第四季度,公司单季度主营收入2.64亿元,同比上升4.82%;单季度归母净利润1536.03万元,同比下降0.75%;单季度扣非净利润1465.1万元,同比上升2.55%;负债率30.82%,投资收益520.0万元,财务费用-38.71万元,毛利率49.51%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600010448.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627291637","title":"恩威医药(301331)2名股东合计质押540万股,占总股本5.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627291637","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627291637?lang=zh_cn&edition=full","pubTime":"2026-04-16 18:23","pubTimestamp":1776335003,"startTime":"0","endTime":"0","summary":"证券之星消息,恩威医药4月16日公开信息显示,股东成都恩威投资(集团)有限公司、成都杰威企业管理有限公司向湖南通程典当有限责任公司合计质押540.0万股,占总股本5.25%。恩威医药主营业务:中成药及化学药的研发、生产及销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041600035820.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617713568","title":"股市必读:恩威医药(301331)3月4日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2617713568","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617713568?lang=zh_cn&edition=full","pubTime":"2026-03-05 02:29","pubTimestamp":1772648950,"startTime":"0","endTime":"0","summary":"截至2026年3月4日收盘,恩威医药报收于27.02元,下跌0.22%,换手率0.99%,成交量1.02万手,成交额2744.28万元。董秘最新回复投资者: 尊敬的董秘 新年好 衷心感谢你们不厌其烦回答投资者的提问。公司股东户数信息将在定期报告中披露,请关注公司在指定信息披露媒体发布的定期报告。当日关注点来自交易信息汇总:3月4日主力资金净流出57.6万元,游资资金净流出211.73万元,散户资金净流入269.32万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030500001315.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613797499","title":"恩威医药(301331)披露全资子公司取得换发《药品生产许可证》公告,2月24日股价上涨1.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613797499","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613797499?lang=zh_cn&edition=full","pubTime":"2026-02-24 18:45","pubTimestamp":1771929917,"startTime":"0","endTime":"0","summary":"截至2026年2月24日收盘,恩威医药报收于29.47元,较前一交易日上涨1.94%,最新总市值为30.32亿元。恩威医药近日披露《关于全资子公司取得换发的〈药品生产许可证〉的公告》。公告显示,公司全资子公司四川恩威制药有限公司近日取得换发的《药品生产许可证》,有效期至2030年7月17日,生产范围包括软膏剂、洗剂、片剂、胶囊剂等;同时,同意其委托湖南泰阳药业有限公司生产姜脑止痛搽剂,分类码相应变更。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400037652.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609301886","title":"恩威医药(301331)披露控股股东部分股份解除质押公告,2月5日股价上涨0.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609301886","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609301886?lang=zh_cn&edition=full","pubTime":"2026-02-05 22:35","pubTimestamp":1770302119,"startTime":"0","endTime":"0","summary":"截至2026年2月5日收盘,恩威医药报收于29.23元,较前一交易日上涨0.1%,最新总市值为30.08亿元。该股当日开盘29.49元,最高29.8元,最低29.0元,成交额达3315.42万元,换手率为1.1%。恩威医药于近日披露《关于控股股东部分股份解除质押的公告》。该笔股份质押起始日为2025年8月18日,质权人为徐英壮,质押用途为自身生产经营。本次解除质押后,恩威集团累计质押股份22,380,000股,占其所持股份86.97%,占公司总股本21.75%。公司表示该事项对生产经营、公司治理无不利影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500039827.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608123860","title":"恩威医药(301331)披露控股股东询价转让结果公告,2月2日股价上涨0.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608123860","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608123860?lang=zh_cn&edition=full","pubTime":"2026-02-02 22:52","pubTimestamp":1770043941,"startTime":"0","endTime":"0","summary":"截至2026年2月2日收盘,恩威医药报收于28.51元,较前一交易日上涨0.11%,最新总市值为29.33亿元。该股当日开盘28.4元,最高29.26元,最低28.39元,成交额达4552.78万元,换手率为1.53%。公司于近日披露《股东询价转让结果报告书暨持股5%以上股东权益变动触及1%整数倍的提示性公告》。本次权益变动后,出让方及一致行动人合计持股比例由69.10%降至65.22%。转让方式为非公开询价转让,不通过集中竞价交易,受让方锁定6个月。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200039613.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606734743","title":"股市必读:恩威医药(301331)1月27日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2606734743","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606734743?lang=zh_cn&edition=full","pubTime":"2026-01-28 02:21","pubTimestamp":1769538070,"startTime":"0","endTime":"0","summary":"截至2026年1月27日收盘,恩威医药报收于29.3元,下跌3.97%,换手率3.84%,成交量3.94万手,成交额1.16亿元。当日关注点来自交易信息汇总:1月27日主力与游资资金均呈净流出态势,散户资金净流入1582.71万元。参与报价的机构投资者共30家,有效认购股份数量为16,476,000股,有效认购倍数为4.12倍。本次询价转让不通过集中竞价或大宗交易方式进行,受让方6个月内不得转让所受让股份。本次转让不涉及公司控制权变更。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800001372.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606210451","title":"恩威医药最新公告:控股股东拟询价转让400万股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2606210451","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606210451?lang=zh_cn&edition=full","pubTime":"2026-01-26 20:40","pubTimestamp":1769431244,"startTime":"0","endTime":"0","summary":"恩威医药(301331.SZ)公告称,公司控股股东成都恩威投资(集团)有限公司计划通过询价转让方式转让400万股股份,占公司总股本的3.89%,占剔除公司已回购股份后的总股本的3.93%。转让原因为自身资金需求。本次询价转让不通过集中竞价交易或大宗交易方式进行,受让方通过询价转让受让的股份,在受让后6个月内不得转让。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600032648.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604919937","title":"恩威医药最新公告:2025年净利润同比预增50.68%至77.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604919937","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604919937?lang=zh_cn&edition=full","pubTime":"2026-01-20 17:49","pubTimestamp":1768902585,"startTime":"0","endTime":"0","summary":"恩威医药(301331.SZ)披露2025年度业绩预告,预计2025年归母净利润为5650万元至6650万元,同比增长50.68%至77.35%。2025年业绩上升的主要原因是主营业务收入增长带来净利润增加及股权激励计划成本摊销减少。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012000028682.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2595782447","title":"恩威医药(301331)披露2025年中期分红派息实施公告,12月31日股价上涨0.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595782447","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595782447?lang=zh_cn&edition=full","pubTime":"2025-12-31 18:11","pubTimestamp":1767175883,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘,恩威医药报收于26.44元,较前一交易日上涨0.23%,最新总市值为27.2亿元。该股当日开盘26.42元,最高26.58元,最低26.25元,成交额达1840.99万元,换手率为0.68%。近日,恩威医药股份有限公司发布2025年中期分红派息实施公告。股权登记日为2026年1月7日,除权除息日为2026年1月8日。分红后将调整相关股东减持价格承诺及限制性股票授予价格。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100033888.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301331"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1779224455825,"stockEarnings":[{"period":"1week","weight":-0.0203},{"period":"1month","weight":0.0076},{"period":"3month","weight":-0.0802},{"period":"6month","weight":-0.0751},{"period":"1year","weight":0.0522},{"period":"ytd","weight":0.0183}],"compareEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":0.0292},{"period":"3month","weight":0.0214},{"period":"6month","weight":0.0607},{"period":"1year","weight":0.2381},{"period":"ytd","weight":0.0506}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"恩威医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"7731人(较上一季度增加14.45%)","perCapita":"13276股","listingDate":"2022-09-21","address":"西藏自治区昌都市卡若区经开区A坝区创业大道恩威大厦","registeredCapital":"10289万元","survey":" 恩威医药股份有限公司的主营业务是中成药、化学药及健康私护用品的研发、生产及销售。公司的主要产品是洁尔阴洗液、洁尔阴软膏、洁尔阴泡腾片、恩威草本抑菌洗液、山麦健脾口服液、化积口服液、健儿药丸、小儿氨酚黄那敏颗粒、小儿咳喘灵颗粒、加味藿香正气合剂、复方氨酚烷胺片、复方银翘氨敏胶囊、抗病毒口服液、六味地黄胶囊、人参养荣膏、益肺健脾颗粒、玉屏风口服液。公司荣获2025年法国好设计奖、2025年美国好设计奖,产品还荣获“2025鸿鼎榜单10万+药房门店明星产品”荣誉称号。","listedPrice":29.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恩威医药(301331)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恩威医药(301331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恩威医药,301331,恩威医药股票,恩威医药股票老虎,恩威医药股票老虎国际,恩威医药行情,恩威医药股票行情,恩威医药股价,恩威医药股市,恩威医药股票价格,恩威医药股票交易,恩威医药股票购买,恩威医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恩威医药(301331)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恩威医药(301331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}